What really happens with post-marketing drug studies

Industry-funded post-marketing studies are not improving drug safety surveillance, according to new data obtained through freedom of information requests.

While regulatory agencies rely on such studies, sample sizes are generally too small to allow the detection of rare adverse drug reactions, and many participating doctors are strictly obliged to maintain confidentiality towards the sponsor, say the authors of the German report.